PTC Therapeutics Issues Inducement Stock Grants to New Hires
PTC Therapeutics approved stock options and RSUs for new employees under a Nasdaq rule that permits equity grants without shareholder approval.
PTC Therapeutics, Inc. announced Monday that it approved inducement equity grants to newly hired employees on Sept. 22, 2026, authorizing non-statutory stock options covering an aggregate of 51,270 shares of common stock along with 37,995 restricted stock units, according to a company statement issued from Warren, N.J.
The grants were made under Nasdaq Listing Rule 5635(c)(4), a provision that allows publicly traded companies to award equity compensation to new employees as an inducement to join the firm without first obtaining shareholder approval — a procedural distinction that signals these recipients are incoming rather than existing staff.
Read more AllianceBernstein Muni Fund AFB Reports Q3 2026 Earnings →
Inducement grants of this type are a common tool among biopharmaceutical companies competing for specialized scientific and commercial talent. By structuring awards under the Nasdaq exemption, PTC Therapeutics can move quickly to close offers without waiting for a shareholder vote, though the grants must still be publicly disclosed.
PTC Therapeutics trades on the Nasdaq Global Select Market under the ticker symbol PTCT and is headquartered in Warren, New Jersey. The company focuses on the development of treatments for rare diseases.
Continue reading at All Financial Services & Investing.
